Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans.

Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. Abstract Text:

Aruna Vedala,Wei Wang,Richard A Neese,Mark P Christiansen,Marc K Hellerstein,

Newly synthesized triglyceride (TG) may exit the liver immediately as VLDL-TG or be stored and secreted after a delay. We quantified the contributions from plasma NEFA, diet, and de novo lipogenesis (DNL) to VLDL-TG via immediate and delayed pathways in five lean, normolipidemic subjects; six obese, hypertriglyceridemic (HPTG) nondiabetics; and six obese, HPTG diabetics. Intravenous [(2)H(31)]palmitate and [1-(13)C(1)] acetate and oral [(2)H(35)]stearate were administered for 30 h preceding an overnight fast. [1,2,3,4-(13)C(4)]palmitate was infused during the subsequent 12 h fast. Contributions from plasma NEFA via the immediate pathway were 64 +/- 15, 33 +/- 6, and 58 +/- 2% in control, HPTG, and diabetic HPTG, respectively. Delayed pool fractional contributions were as follows: dietary FA, 2.0 +/- 0.9, 2.5 +/- 1, and 12 +/- 2%; DNL, 3 +/- 0.3, 14 +/- 3, and 13 +/- 4%; delayed NEFA, 15 +/- 4, 20 +/- 4, and 30 +/- 3%. VLDL-TG production rates and absolute input rates from the delayed pool were significantly higher in HPTG and diabetic HPTG than in controls. In conclusion, we provide direct kinetic evidence for a hepatic TG storage pool in humans and document its metabolic sources. The turnover time and sources of this pool differ in diabetic HPTG and nondiabetic HPTG, with potential therapeutic implications.

Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. Publishing Authors By Initials

A Vedala,W Wang,RA Neese,MP Christiansen,MK Hellerstein,

For similar lipids: glycerides: triglycerides research abstracts see: lipids: glycerides: triglycerides research

PUBMED ID PMID:

MEDLINE DATE:

Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of lipid research

VOLUME: 47

Page Numbers: 2562-74

Journal Abbreviation: J. Lipid Res.

ISSN: 0022-2275

DAY: 23

MONTH: 08

YEAR: 2006

Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 376606

Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. Keywords Mesh Terms:

KEYWORDS: Triglycerides

MESH TERMS: metabolism

Chemical & Substance for Abstract: Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans. Information

Substance Name: very low density lipoprotein triglycerid

Registry Number: 0

Grant and Affiliation Information for Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans.

AFFILIATION: Department of Nutritional Sciences and Toxicology, University of California at Berkeley, Berkeley, CA 94720, USA.

Country: United States

AGENCY: United States NCRR

GRANT: M01-RR00083

ACRONYM: RR

MEDLINETA: J Lipid Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans Related Publications

• Atrial infarction with diagnostic electrocardiographic findings.
• Delayed secretory pathway contributions to VLDL-triglycerides from plasma NEFA, diet, and de novo lipogenesis in humans.
• Divergent Fates of the Medical Humanities in Psychiatry and Internal Medicine: Should Psychiatry be Rehumanized?
• Do calorie restriction or alternate-day fasting regimens modulate adipose tissue physiology in a way that reduces chronic disease risk?
• Effects of modified alternate-day fasting regimens on adipocyte size, triglyceride metabolism, and plasma adiponectin levels in mice.
• Exploiting complexity and the robustness of network architecture for drug discovery.
• FOLATE METABOLISM AND IRON DEFICIENCY.
• Heavy water labeling of DNA for measurement of cell proliferation and recruitment during primary murine lymph node responses against model antigens.
• Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery.
• Measurement of cell proliferation by heavy water labeling.
• Measurement of pancreatic islet cell proliferation by heavy water labeling.
• Measurement of very low rates of cell proliferation by heavy water labeling of DNA and gas chromatography/pyrolysis/isotope ratio-mass spectrometric analysis.
• Modified alternate-day fasting regimens reduce cell proliferation rates to a similar extent as daily calorie restriction in mice.
• Pharmacological doses of dietary curcumin increase colon epithelial cell proliferation in vivo in rats.
• Practice-based evidence rather than evidence-based practice in psychiatry.
• Prophylaxis against streptococcic infection in an adult rheumatic population.
• The disappearing patient.
• The incidence of heart disease in 2,000 consecutive autopsies.
• [Exercise therapy in the rehabilitation and secondary prevention of coronary heart disease]